statements

The stock has been placed in Additional Surveillance Measure (ASM) list STASM - I.

Gennex Laboratories Ltd.

BSE: 531739

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

12.18+0.0 (+0.25%)

26 Aug, 12:00 AM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Gennex Laboratories Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS	12M IR
Total Revenue	24.56	29.92	34.99	31.90	38.56	41.91	43.78	55.80	55.62	59.65	61.21	65.60	86.71	137.90	172.74	178.41
Cost of Operating Revenue	19.37	24.85	27.71	24.66	13.14	24.77	27.65	33.68	34.63	36.60	38.89	40.83	51.22	99.07	131.17	138.68
Gross Profit	5.20	5.08	7.28	7.24	25.41	17.14	16.13	22.12	20.99	23.05	22.32	24.77	35.49	38.83	41.57	39.73
Gross Margin	21.2	17.0	20.8	22.7	65.9	40.9	36.8	39.6	37.7	38.6	36.5	37.8	40.9	28.2	24.1	22.3
Total Operating Expenses	23.64	29.19	34.18	30.76	35.20	38.22	42.51	52.76	53.38	54.00	56.62	61.83	72.05	123.33	153.55	159.98
Operating Profit	0.92	0.73	0.81	1.14	3.36	3.69	1.27	3.04	2.24	5.65	4.59	3.77	14.66	14.57	19.19	18.43
Operating Margin	3.8	2.4	2.3	3.6	8.7	8.8	2.9	5.4	4.0	9.5	7.5	5.8	16.9	10.6	11.1	10.3
Financing Income/(Expense) - Net	-0.27	-0.28	-0.32	-0.48	-0.50	-0.71	-0.73	-0.79	-0.75	-0.74	-0.88	-1.35	-3.08	-3.61	-4.20	-4.12
Profit before Taxes	0.66	0.47	0.70	0.85	3.03	3.10	1.45	3.03	2.55	5.06	5.09	6.37	16.49	21.40	23.24	22.29
Income Taxes	0.28	0.08	0.49	0.19	0.70	0.40	0.62	0.81	0.69	1.02	1.17	1.45	3.32	3.27	2.26	1.66
Profit after Tax	0.38	0.40	0.21	0.65	2.34	2.70	0.84	2.22	1.86	4.04	3.92	4.92	13.18	18.12	18.46	18.67
PAT Margin	1.5	1.3	0.6	2.1	6.1	6.5	1.9	4.0	3.3	6.8	6.4	7.5	15.2	13.1	10.7	10.5
EPS - Basic - ex Extraordinary Items	0.03	0.03	0.02	0.05	0.18	0.20	0.06	0.17	0.14	0.30	0.30	0.34	0.71	0.80	0.76	0.77
EPS - Diluted - ex Extraordinary Items	0.03	0.03	0.02	0.05	0.18	0.20	0.06	0.17	0.14	0.30	0.30	0.34	0.71	0.80	0.76	0.77
EBIT	0.92	0.73	0.81	1.14	3.36	3.69	1.27	3.04	2.24	5.65	4.59	3.77	14.66	14.57	19.19	18.43
EBITDA	1.67	1.53	1.63	2.02	4.20	4.53	2.19	4.02	3.25	6.53	5.38	4.69	17.03	16.57	21.84	21.14
EBITDA Margin	6.8	5.1	4.6	6.3	10.9	10.8	5.0	7.2	5.8	11.0	8.8	7.2	19.6	12.0	12.6	11.9

Balance Sheet

Abridged

Understanding Balance Sheet

Gennex Laboratories Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	R 2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	R 2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	IR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	10.36	12.40	16.32	17.31	18.96	26.24	27.66	29.04	34.97	37.67	47.18	48.68	161.81	181.13	264.66
Long-Term Investments	7.01	7.01	7.01	7.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Property Plant & Equipment - Net	16.19	15.97	16.11	14.70	15.58	15.74	15.58	15.64	14.93	14.13	13.70	67.65	55.02	61.82	71.11
Total Non-Current Assets	24.02	23.95	23.27	21.89	22.83	22.97	22.80	22.69	22.16	21.23	20.84	83.63	68.17	74.91	84.02
Total Assets	34.38	36.35	39.59	39.20	41.79	49.21	50.47	51.73	57.13	58.90	68.03	132.32	229.99	256.04	348.68
Total Current Liabilities	7.69	9.57	12.39	12.52	12.42	17.14	17.66	17.30	20.86	19.04	24.21	29.51	40.30	44.56	72.40
Long Term Debt	0.21	0.09	0.31	0.22	0.03	0.09	0.35	-	-	-	-	16.29	13.22	14.06	-
Total Non-Current Liabilities	1.90	1.60	1.81	1.15	1.13	1.13	1.04	0.56	0.40	0.15	0.00	16.29	13.22	16.89	43.44
Total Liabilities	9.59	11.17	14.20	13.68	13.55	18.27	18.70	17.86	21.26	19.19	24.21	45.80	53.52	61.45	115.84
Total Shareholders' Equity	24.78	25.18	25.39	25.53	28.24	30.94	31.77	33.87	35.87	39.71	43.82	80.35	170.38	186.69	222.52
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	6.17	6.08	7.90	10.32
Total Equity	24.78	25.18	25.39	25.53	28.24	30.94	31.77	33.87	35.87	39.71	43.82	86.52	176.46	194.59	232.84
Total Liabilities & Equity	34.38	36.35	39.59	39.20	41.79	49.21	50.47	51.73	57.13	58.90	68.03	132.32	229.99	256.04	348.68

Cash Flow

Abridged

Understanding Cash Flow Statement

Gennex Laboratories Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	1.40	1.02	1.19	1.36	3.53	3.24	1.35	0.00	3.55	4.41	4.95	7.29	18.86	20.17	23.68
Working Capital - Increase/(Decrease)	0.50	-3.00	-0.97	-1.59	-0.63	-4.03	1.16	0.00	-5.90	-6.54	5.18	17.69	-64.83	-25.00	-84.39
Net CF from Operating Activities	1.90	-1.99	0.22	-0.23	2.90	-0.79	2.51	0.00	-2.35	-2.13	10.13	24.98	-45.97	-4.83	-60.71
Capital Expenditures - Net	0.93	0.59	0.96	0.24	1.19	1.00	0.75	0.00	0.29	0.08	1.57	39.74	-15.35	8.75	11.94
Net CF from Investing Activities	-0.93	-0.59	-0.96	-0.24	-1.19	-1.00	-0.75	0.00	-0.29	-0.08	-1.57	-40.99	15.12	-8.75	-11.94
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	-	-	-	-	-	30.44	79.83	-	17.22
Debt - LT & ST - Issuance/(Retirement) - Total	0.35	0.51	0.77	0.66	-1.41	1.57	-1.37	0.00	0.41	2.36	-0.95	-8.05	-3.07	8.17	52.28
Net Cash Flow from Financing Activities	0.35	0.51	0.77	0.66	-1.41	1.57	-1.37	0.00	0.41	2.36	-0.95	22.39	76.76	8.17	69.50
Free Cash Flow to Equity	1.32	-2.07	0.03	0.19	0.29	-0.22	0.39	0.00	-2.23	0.16	7.61	-22.80	-33.69	-5.41	-20.37
Free Operating CF net dividend	0.97	-2.58	-0.75	-0.47	1.64	-1.79	1.75	-	-2.64	-2.21	8.54	-14.80	-45.97	-13.78	-72.65
Free Operating CF	0.97	-2.58	-0.75	-0.47	1.64	-1.79	1.75	-	-2.64	-2.21	8.54	-14.80	-45.97	-13.78	-72.65

Business Segment Analysis

FY End:

Mar 10

Gennex Laboratories Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 8.08 CrOther Business (0.0%)₹ 0.00 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 15.45 Cr

Assets

Pharmaceuticals (100.0%)₹ 30.14 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 0.68 CrOther Business (0.0%)₹ 0.00 Cr

Regional Segment Analysis

FY End:

Mar 12

Gennex Laboratories Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Within India (52.1%)₹ 12.80 CrExport others (25.0%)₹ 6.15 CrDubai (11.8%)₹ 2.90 CrNetherlands (10.1%)₹ 2.48 CrGermany (1.0%)₹ 0.24 Cr

Assets

Within India (55.6%)₹ 1.86 CrExport others (43.3%)₹ 1.45 CrDubai (1.1%)₹ 0.04 Cr

Historical Segment Analysis

Track how Gennex Laboratories Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2010 Mar 31
	2010 Mar 31
Pharmaceuticals	8
Other Business	0

Frequently Asked Questions

What is the revenue of Gennex Laboratories Ltd.?

The latest trailing twelve month revenue of Gennex Laboratories Ltd. is ₹ 178.40 Cr, reflecting a 1-year growth of 24.10% and a 3-year CAGR of 37.82%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Gennex Laboratories Ltd.?

The latest trailing twelve month net profit (PAT) of Gennex Laboratories Ltd. is ₹ 18.67 Cr, with a 3-year earnings CAGR of 23.13%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Gennex Laboratories Ltd.?

The trailing twelve month EBITDA of Gennex Laboratories Ltd. is approximately ₹ 18.43 Cr (based on an operating margin of 10.33%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Gennex Laboratories Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Gennex Laboratories Ltd. is 0.77. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Gennex Laboratories Ltd.?

The debt-to-equity ratio of Gennex Laboratories Ltd. stands at 0.16. The interest coverage ratio is 4.47x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Gennex Laboratories Ltd.?

The estimated book value per share of Gennex Laboratories Ltd. is 9.78 (derived from a P/B ratio of 1.24 and market price of ₹ 12.18), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Gennex Laboratories Ltd.?

The trailing twelve month operating cash flow of Gennex Laboratories Ltd. is ₹ -60.71 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Gennex Laboratories Ltd. report consolidated or standalone financials?

Gennex Laboratories Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.